FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 340:351-357 February 4, 1999 Number 5 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Platinum-based chemotherapy is the cornerstone of modern treatment for ovarian, testicular, and other cancers, but few investigations have quantified the late sequelae of such treatment.

Methods We conducted a case–control study of secondary leukemia in a population-based cohort of 28,971 women in North America and Europe who had received a diagnosis of invasive ovarian cancer between 1980 and 1993. Leukemia developed after the administration of platinum-based therapy in 96 women. These women were matched to 272 control patients. The type, cumulative dose, and duration of chemotherapy and the dose of radiation delivered to active bone marrow were compared in the two groups.

Results Among the women who received platinum-based combination chemotherapy for ovarian cancer, the relative risk of leukemia was 4.0 (95 percent confidence interval, 1.4 to 11.4). The relative risks for treatment with carboplatin and for treatment with cisplatin were 6.5 (95 percent confidence interval, 1.2 to 36.6) and 3.3 (95 percent confidence interval, 1.1 to 9.4), respectively. We found evidence of a dose–response relation, with relative risks reaching 7.6 at doses of 1000 mg or more of platinum (P for trend <0.001). Radiotherapy without chemotherapy (median dose, 18.4 Gy) did not increase the risk of leukemia.

Conclusions Platinum-based treatment of ovarian cancer increases the risk of secondary leukemia. Nevertheless, the substantial benefit that platinum-based treatment offers patients with advanced disease outweighs the relatively small excess risk of leukemia.

Source Information

From the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md. (L.B.T., R.E.C.); Cancer Care Ontario, Toronto (E.J.H.); Karolinska University Hospital, Stockholm, Sweden (K.B., P.H.); the University of Iowa, Iowa City (C.F.L.); the Department of Health and Senior Services, Trenton, N.J. (B.A.K.); Helsinki University Central Hospital, Helsinki, Finland (T.W.); Danish Cancer Society, Copenhagen, Denmark (M.A.); Finnish Cancer Registry, Helsinki, Finland (E.P.); Princess Margaret Hospital, University of Toronto, Toronto (J.S.); and the University of Texas M.D. Anderson Cancer Center, Houston (M.S.). Other authors were Hans Storm, M.D., Danish Cancer Society, Copenhagen, Denmark; E. Aileen Clarke, M.D., Cancer Care Ontario, Toronto; John D. Boice, Jr., Sc.D., Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md.; and Mary Gospodarowicz, M.D., Princess Margaret Hospital, University of Toronto, Toronto.

Address reprint requests to Dr. Travis at the National Cancer Institute, Executive Plaza N., Suite 408, Bethesda, MD 20892.

Full Text of this Article

This article has been cited by other articles:

• Lichtman, M. A. (2008). Is There an Entity of Chemically Induced BCR-ABL-Positive Chronic Myelogenous Leukemia?. The Oncologist 13: 645-654 [Abstract] [Full Text]  
• Powles, T., Robinson, D., Shamash, J., Moller, H., Tranter, N., Oliver, T. (2008). The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol 19: 443-447 [Abstract] [Full Text]  
• Trope, C., Kaern, J. (2007). Adjuvant Chemotherapy for Early-Stage Ovarian Cancer: Review of the Literature. JCO 25: 2909-2920 [Abstract] [Full Text]  
• Henderson, T. O., Whitton, J., Stovall, M., Mertens, A. C., Mitby, P., Friedman, D., Strong, L. C., Hammond, S., Neglia, J. P., Meadows, A. T., Robison, L., Diller, L. (2007). Secondary Sarcomas in Childhood Cancer Survivors: A Report From the Childhood Cancer Survivor Study. JNCI J Natl Cancer Inst 99: 300-308 [Abstract] [Full Text]  
• Bhatia, S., Krailo, M. D., Chen, Z., Burden, L., Askin, F. B., Dickman, P. S., Grier, H. E., Link, M. P., Meyers, P. A., Perlman, E. J., Rausen, A. R., Robison, L. L., Vietti, T. J., Miser, J. S. (2007). Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: a report from the Children's Oncology Group. Blood 109: 46-51 [Abstract] [Full Text]  
• Travis, L. B. (2006). The Epidemiology of Second Primary Cancers. Cancer Epidemiol. Biomarkers Prev. 15: 2020-2026 [Abstract] [Full Text]  
• Worrillow, L. J., Travis, L. B., Smith, A. G., Rollinson, S., Smith, A. J., Wild, C. P., Holowaty, E. J., Kohler, B. A., Wiklund, T., Pukkala, E., Roman, E., Morgan, G. J., Allan, J. M. (2003). An Intron Splice Acceptor Polymorphism in hMSH2 and Risk of Leukemia after Treatment with Chemotherapeutic Alkylating Agents. Clin. Cancer Res. 9: 3012-3020 [Abstract] [Full Text]  
• Travis, L. B., Hill, D. A., Dores, G. M., Gospodarowicz, M., van Leeuwen, F. E., Holowaty, E., Glimelius, B., Andersson, M., Wiklund, T., Lynch, C. F., Van't Veer, M. B., Glimelius, I., Storm, H., Pukkala, E., Stovall, M., Curtis, R., Boice, J. D. Jr, Gilbert, E. (2003). Breast Cancer Following Radiotherapy and Chemotherapy Among Young Women With Hodgkin Disease. JAMA 290: 465-475 [Abstract] [Full Text]  
• Kattlove, H., Winn, R. J. (2003). Ongoing Care of Patients After Primary Treatment for Their Cancer. CA Cancer J Clin 53: 172-196 [Abstract] [Full Text]  
• Metayer, C., Curtis, R. E., Vose, J., Sobocinski, K. A., Horowitz, M. M., Bhatia, S., Fay, J. W., Freytes, C. O., Goldstein, S. C., Herzig, R. H., Keating, A., Miller, C. B., Nevill, T. J., Pecora, A. L., Rizzo, J. D., Williams, S. F., Li, C.-Y., Travis, L. B., Weisdorf, D. J. (2003). Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 101: 2015-2023 [Abstract] [Full Text]  
• Buschfort-Papewalis, C., Moritz, T., Liedert, B., Thomale, J. (2002). Down-regulation of DNA repair in human CD34+ progenitor cells corresponds to increased drug sensitivity and apoptotic response. Blood 100: 845-853 [Abstract] [Full Text]  
• Leonard, D. G. B., Travis, L. B., Addya, K., Dores, G. M., Holowaty, E. J., Bergfeldt, K., Malkin, D., Kohler, B. A., Lynch, C. F., Wiklund, T., Stovall, M., Hall, P., Pukkala, E., Slater, D. J., Felix, C. A. (2002). p53 Mutations in Leukemia and Myelodysplastic Syndrome after Ovarian Cancer. Clin. Cancer Res. 8: 973-985 [Abstract] [Full Text]  
• Travis, L. B., Gospodarowicz, M., Curtis, R. E., Aileen Clarke, E., Andersson, M., Glimelius, B., Joensuu, T., Lynch, C. F., van Leeuwen, F. E., Holowaty, E., Storm, H., Glimelius, I., Pukkala, E., Stovall, M., Fraumeni, J. F. Jr., Boice, J. D. Jr., Gilbert, E. (2002). Lung Cancer Following Chemotherapy and Radiotherapy for Hodgkin's Disease. JNCI J Natl Cancer Inst 94: 182-192 [Abstract] [Full Text]  
• Nishimura, S.-i., Sato, T., Ueda, H., Ueda, K., Beck, M. N., Meisler, A., Hortobagyi, G. N., Ueno, N., Hung, M.-C., Mokbel, K., Elkak, A. E. (2001). Acute Myeloblastic Leukemia as a Second Malignancy in a Patient With Hereditary Retinoblastoma. JCO 19: 4182-4183 [Full Text]  
• Allan, J. M., Wild, C. P., Rollinson, S., Willett, E. V., Moorman, A. V., Dovey, G. J., Roddam, P. L., Roman, E., Cartwright, R. A., Morgan, G. J. (2001). Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc. Natl. Acad. Sci. USA 10.1073/pnas.191211198v1 [Abstract] [Full Text]  
• Neglia, J. P., Friedman, D. L., Yasui, Y., Mertens, A. C., Hammond, S., Stovall, M., Donaldson, S. S., Meadows, A. T., Robison, L. L. (2001). Second Malignant Neoplasms in Five-Year Survivors of Childhood Cancer: Childhood Cancer Survivor Study. JNCI J Natl Cancer Inst 93: 618-629 [Abstract] [Full Text]  
• Rose, P. G., Rodriguez, M., Waggoner, S., Greer, B. E., Horowitz, I. R., Fowler, J. M., McGuire, W. P. (2000). Phase I Study of Paclitaxel, Carboplatin, and Increasing Days of Prolonged Oral Etoposide in Ovarian, Peritoneal, and Tubal Carcinoma: A Gynecologic Oncology Group Study. JCO 18: 2957-2962 [Abstract] [Full Text]  
• Travis, L. B., Andersson, M., Gospodarowicz, M., van Leeuwen, F. E., Bergfeldt, K., Lynch, C. F., Curtis, R. E., Kohler, B. A., Wiklund, T., Storm, H., Holowaty, E., Hall, P., Pukkala, E., Sleijfer, D. T., Clarke, E. A., Boice, J. D. Jr., Stovall, M., Gilbert, E. (2000). Treatment-Associated Leukemia Following Testicular Cancer. JNCI J Natl Cancer Inst 92: 1165-1171 [Abstract] [Full Text]  
• Piver, M. S., Muggia, F. M., Brady, M. F., Alvarez, R. (2000). Maintenance Chemotherapy in Advanced Ovarian Cancer. JCO 18: 1803-1805 [Full Text]  
• Allan, J. M., Wild, C. P., Rollinson, S., Willett, E. V., Moorman, A. V., Dovey, G. J., Roddam, P. L., Roman, E., Cartwright, R. A., Morgan, G. J. (2001). Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc. Natl. Acad. Sci. USA 98: 11592-11597 [Abstract] [Full Text]